NEWS & EVENTS 
SPECIALTY CARE
DOWNLOAD THE MCT2D PCP Performance Measure uACR Year 1 Details Document
Why uACR Matters
MCT2D’s next performance measure will focus on urine albumin-to-creatinine ratio (uACR) screening, a critical tool for the early detection of diabetic kidney disease—which affects nearly 1 in 3 adults with type 2 diabetes.
Detecting elevated uACR levels enables earlier intervention, slowing the progression to end-stage kidney disease and reducing cardiovascular risk. Routine screening supports guideline-based, proactive care and improves long-term outcomes.
How Our Measure Compares to HEDIS
The MCT2D uACR measure is closely aligned with the HEDIS Kidney Health Evaluation definition, with two key differences:
- It focuses exclusively on adults with type 2 diabetes.
- It does not include eGFR in the evaluation at this time.
Why This Alignment Matters:
- Reduces burden: Aligning with widely used measures allows practices to streamline efforts across programs and prevents quality improvement fatigue.
- Leverages strong data: Metrics like A1c and uACR are well-supported by the MCT2D registry, offering reliable and complete data for analysis.
WHAT is the performance goal?
- Practices must achieve a 10% absolute improvement from their baseline screening rate (e.g., 54.5% → 64.5%), up to a maximum goal of 90%.
- Practices with a baseline between 80% and 90% only need to reach 90% (e.g., 87.5% → 90%).
- Practices already above 90% must repeat their 90% rate during the measurement year.
WHO is included in the uACR Measure?
Eligible patients are those who:
- Are aged 18–85
- Are attributed to an MCT2D-participating primary care practice
- Meet MCT2D’s type 2 diabetes registry criteria, which is:
- Type 2 diabetes diagnosis AND/OR
- Most recent clinical A1C >= 6.5 AND/OR
- Diabetes medication filled within the past six months AND/OR
- Exclusion: Diagnosed with type 1 diabetes
- Had at least one claim for any service during the 14-month baseline period (ensuring the patient appears in MCT2D’s claims data)
WHEN is the measurement and payment timeline?
Measurement Timeline: July 1, 2025- August 31, 2026
Payment Cycle: This measure will be included in the Value-Based Reimbursement (VBR) payment cycle that begins September 1, 2027.
Reports
- Baseline report: May 2025 (Available Now)
- October 2025
- March 2026
- August 2026
- Final performance report: February 2027
Access Your Practice's uACR Baseline Report
Baseline reports are now available on the MCT2D Admin Portal.
- Baseline measurement period: January 1, 2024 – February 28, 2025
- Each practice is measured individually, based on its own attributed patient population.
- Note: We are no longer aggregating smaller practices into aggregate groups—each practice will be assessed separately.
How to Access Your Report
- In the left-hand menu, click “uACR Baseline Reports.”
- Your report will include:
- Number of attributed patients
- Your practice’s baseline uACR screening rate
- Your target improvement rate
- The number of additional patients needed to reach your goal
Need an Admin Portal Account?
- Click “Apply for an Account.”
- Your request will be sent to your Physician Organization (PO) for approval.
- Once approved, you will receive an email to set your password.
Don’t want an account?
Ask your PO to share your practice’s uACR baseline report directly.
How MCT2D Will Support Your Practice
MCT2D is committed to helping participating practices succeed in improving urine albumin-to-creatinine ratio (uACR) screening. Throughout the 2025–2026 performance year, the Coordinating Center will offer the following support:
- Patient-facing materials, including handouts and clinic posters that highlight the importance of uACR testing
- Individualized support for practices, provided in partnership with the National Kidney Foundation of Michigan (NKFM)
- Best practice sharing, featuring presentations from high-performing sites at MCT2D regional meetings
Have an idea or suggestion for MCT2D?
We’d love to hear from you! Email the Coordinating Center at cceam@mct2d.org.
Subscribe to the MCT2D Newsletter
Once per month we deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.